EARLY DIABETES INTERVENTION PROGRAM (EDIP)

早期糖尿病干预计划 (EDIP)

• 批准号: 6263500
• 负责人: JANET MCGILL
• 金额: $ 2.44万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263500
• 关键词: clinical research; diabetes mellitus; diabetes mellitus therapy; enzyme inhibitors; glucose clamp technique; glycosidases; human subject; human therapy evaluation; hypoglycemic agents; insulin; insulin sensitivity /resistance; longitudinal human study

This is an investigator-initiated, partially industry-supported, two-center, randomized, placebo controlled trial of the a-glucosidase inhibitor acarbose(Precose, Bayer Pharmaceuticals, Inc.) in adults with early postprandial diabetes mellitus. Subjects will be followed up to 5 years for the development of overt diabetes mellitus with fasting hyperglycemia. They will also have evaluations for diabetes complications. Half(50%) of the volunteers will undergo a yearly evaluation to assess insulin secretion and sensitivity using a hyperglycemic clamp study.

这是一项研究者发起、部分行业支持、双中心、随机、安慰剂对照的a-葡萄糖苷酶抑制剂阿卡波糖（Precose，拜耳制药公司）治疗早期餐后糖尿病成人的试验。受试者将被随访5年，以确定是否有明显的糖尿病伴空腹高血糖。他们还将接受糖尿病并发症的评估。一半（50%）的志愿者将接受每年一次的评估，使用高血糖钳研究来评估胰岛素分泌和敏感性。